GMP – Page 70 – Pharma.Tips

Weak management oversight during regulatory inspection – root cause analysis inspectors expect

Understanding Weak Management Oversight During Regulatory Inspections: A Playbook for Pharmaceutical Professionals In the complex landscape of pharmaceutical manufacturing, weak management oversight can lead to significant regulatory challenges during inspections.…

Inconsistent GMP interpretation during technology transfer – CAPA framework to prevent recurrence

“`html Addressing Discrepancies in GMP Understanding During Technology Transfer: A CAPA Framework In the world of pharmaceutical manufacturing, a common challenge arises during technology transfers: inconsistent interpretations of Good Manufacturing…

Equipment downtime due to cleaning during CPV review – inspection-ready cleaning optimization

Managing Equipment Downtime During Cleaning: Strategies for Effective CPV Review Optimization In the pharmaceutical manufacturing environment, equipment downtime due to cleaning processes during Continued Process Verification (CPV) reviews can significantly…

Repeated GMP deviations during internal audit – FDA/EMA inspection citation risk

Addressing Recurring GMP Deviations During Internal Audits to Mitigate Inspection Risks Frequent and unresolved Good Manufacturing Practice (GMP) deviations can significantly elevate the risk of receiving citations during FDA, EMA,…

Repeated GMP deviations during internal audit – FDA/EMA inspection citation risk

Managing Repeated GMP Deviations during Internal Audits to Mitigate FDA/EMA Inspection Risks Frequent GMP deviations identified during internal audits pose significant risks for pharmaceutical manufacturing facilities, especially when they could…

Batch documentation gaps during technology transfer – how to rebuild GMP maturity

Addressing Batch Documentation Gaps During Technology Transfer to Enhance GMP Compliance In the lifecycle of pharmaceuticals, technology transfer is a critical process, often fraught with challenges, particularly when it comes…

Poor change control discipline during internal audit – CAPA framework to prevent recurrence

Addressing Poor Change Control Practices in Internal Audits: A Comprehensive CAPA Framework In pharmaceutical manufacturing, poor change control discipline can lead to significant compliance risks, impacting product quality and regulatory…

Redundant cleaning steps during equipment changeover – validated efficiency improvement

Improving Validated Efficiency by Addressing Redundant Cleaning Steps in Equipment Changeover Pharmaceutical manufacturers often face challenges with redundant cleaning steps during equipment changeover, leading to prolonged downtime and inefficiencies in…

Tag: GMP

Weak management oversight during regulatory inspection – root cause analysis inspectors expect

Inconsistent GMP interpretation during technology transfer – CAPA framework to prevent recurrence

Equipment downtime due to cleaning during CPV review – inspection-ready cleaning optimization

Repeated GMP deviations during internal audit – FDA/EMA inspection citation risk

Repeated GMP deviations during internal audit – FDA/EMA inspection citation risk

Batch documentation gaps during technology transfer – how to rebuild GMP maturity

Poor change control discipline during internal audit – CAPA framework to prevent recurrence

Redundant cleaning steps during equipment changeover – validated efficiency improvement

Batch documentation gaps during scale-up – root cause analysis inspectors expect

Weak management oversight during technology transfer – FDA/EMA inspection citation risk

Poor change control discipline during technology transfer – FDA/EMA inspection citation risk

Manual cleaning variability during CPV review – inspection-ready cleaning optimization